Results 171 to 180 of about 51,155 (263)

Acute graft versus host disease postliver transplant with mucocutaneous manifestations and pancytopenia: Remission with Janus kinase inhibitor. [PDF]

JAAD Case Rep
Mendoza R, Liu L, Sam A, Abdel-Azim H, Greas M, Dao H.   +5 more
europepmc   +1 more source

Increased Levels of Inflammatory Proteins, Including TARC/CCL17, in Skin of AD Patients During JAK Inhibitor Treatment

Clinical &Experimental Allergy, Volume 55, Issue 3, Page 260-263, March 2025.
Celeste M. Boesjes, Lian F. van der Gang, Daphne S. Bakker, C. F. den Hartog Jager, Marlies de Graaf, Marjolein S. de Bruin‐Weller, Femke van Wijk, Edward F. Knol   +7 more
wiley   +1 more source

Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. [PDF]

Calcif Tissue Int
Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, Müller-Ladner U, Lange U, Klemm P.   +6 more
europepmc   +1 more source

National and Individual‐Level Economic Burden of Local Corticosteroid Use and Concomitant Use of Multiple Local Corticosteroid Formulations—A Nationwide Cohort Study

Clinical &Experimental Allergy, EarlyView.
Kjell Erik Julius Håkansson, Jonas Bækdal, Inge Raadal Skov, Steven Arild Wuyts Andersen, Zarqa Ali, Anders Løkke, Rikke Ibsen, Ole Hilberg, Howraman Meteran, Claus Rikard Johnsen, Vibeke Backer, Charlotte Suppli Ulrik   +11 more
wiley   +1 more source

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source

Aggressive cutaneous squamous cell carcinoma in a patient on Janus-kinase inhibitor therapy. [PDF]

JAAD Case Rep
Aragon Sierra AM, Donohoe KJ, Canaday DJ, Gomez ED, Jalisi SM, Koomey MM, Aviles VM, Yu KK.   +7 more
europepmc   +1 more source

Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY‐1 and MOMENTUM Trials

European Journal of Haematology, EarlyView.
In this post hoc analysis of the phase 3 SIMPLIFY‐1 and MOMENTUM trials, the number of patients with baseline hemoglobin < 10 g/dL who achieved hemoglobin ≥ 10 g/dL by week 24 with momelotinib, as well as the time to achievement, were evaluated. Patients who were JAK inhibitor naive and/or had moderate anemia were more likely and faster to achieve this
Francesca Palandri, Casey O'Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez‐Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta   +11 more
wiley   +1 more source

Corrigendum to 'Combination of Janus kinase inhibitor and biologic for recalcitrant severe atopic dermatitis'. [PDF]

J Eur Acad Dermatol Venereol
europepmc   +1 more source

Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons. [PDF]

Int J Mol Sci
Vazquez E, Richter F, Natura G, König C, Eitner A, Schaible HG.   +5 more
europepmc   +1 more source

Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin‐Homing T Cells of Atopic Dermatitis Patients

Clinical &Experimental Allergy, EarlyView.
Ahmed M. I. Elfiky, Hidde M. Smits, Marlot van der Wal, Coco Dekkers, Celeste M. Boesjes, Julia Drylewicz, Marjolein de Bruin‐Weller, Femke van Wijk   +7 more
wiley   +1 more source